Summary: In adults with type 2 diabetes prone to postprandial hypotension, a double-blind, placebo-controlled crossover study reported that metformin attenuated the postprandial fall in blood pressure and reduced the number of postprandial hypotension events compared with placebo. These effects were accompanied by higher plasma GLP-1, slower gastric emptying, and an increased heart rate, suggesting a cardiovascular action of metformin that is at least partly independent of glucose lowering. The abstract describes the direction of these findings but does not report the underlying effect sizes, confidence intervals, or p-values.
PICO Summary
| Element | Detail |
|---|---|
| Population | Adults with type 2 diabetes susceptible to postprandial hypotension; double-blind, placebo-controlled, randomised crossover design (Australia/Germany collaboration). The published abstract does not state the enrolled sample size. |
| Intervention | Oral metformin given before a standardised meal, with postprandial measurements; as a crossover study each participant served as their own control. The abstract does not specify the milligram dose. |
| Comparison | Matching placebo within the same participants, under the same meal-test conditions. |
| Outcome | Metformin attenuated the postprandial decrease in blood pressure and reduced postprandial hypotension events versus placebo. This was associated with augmented plasma GLP-1, slowed gastric emptying, and an increased heart rate. The authors frame these as novel cardiovascular effects of metformin independent of glucose lowering. No effect sizes, 95% confidence intervals, p-values, or absolute risk reduction/NNT are reported in the abstract; the magnitude of benefit therefore cannot be quantified from the available data. |
Expert Commentary
The verdict here is a cautious positive: this is a hypothesis-generating mechanistic crossover study, not a clinical efficacy trial. Within its own design it is reasonably clean, since a double-blind, placebo-controlled crossover lets each participant act as their own control and reduces between-person confounding. The signal is coherent and physiologically plausible. A higher postprandial GLP-1 level, slower gastric emptying, and a faster heart rate together offer a believable pathway by which metformin could blunt the blood pressure fall that follows a meal and reduce postprandial hypotension events. The single most important limitation is interpretive. The published abstract reports only the direction of effect and gives no sample size, no dose, and no effect sizes, confidence intervals, or p-values, so the magnitude and precision of any benefit remain unknown, and the supplementary cross-check suggested the response may differ between acute and longer dosing. Small crossover physiology studies are also prone to carryover and period effects, and surrogate endpoints such as postprandial pressure do not automatically translate into fewer falls, fewer syncopal episodes, or better outcomes. Can I use this with my patients? Not yet as a reason to start or continue metformin specifically for postprandial hypotension. It is a mechanistic insight that may reassure a patient with type 2 diabetes and symptomatic postprandial dizziness who is already on metformin. I would like to see a larger trial with reported effect sizes and patient-centred endpoints before changing practice.
References
Quast DR, Xie C, Bound MJ, Grivell J, Hatzinikolas S, Jones KL, Horowitz M, Rayner CK, Nauck MA, Meier JJ, Phillips LK, Wu T. Effects of Metformin on Postprandial Blood Pressure, Heart Rate, Gastric Emptying, GLP-1, and Prevalence of Postprandial Hypotension in Type 2 Diabetes: A Double-Blind Placebo-Controlled Crossover Study. Diabetes. 2025;74(4):611-618. doi:10.2337/db24-0830